Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), for the Treatment of Patients with Multiple Myeloma

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy